Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult Acquired Thrombotic Thrombocytopenic Purpura: A Phase II, Multicenter Non-inferiority Single-arm Study.

NCT04720261 is registered in ClinicalTrials.gov with University Hospital, Rouen as lead sponsor.

NCT NCT04720261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04720261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult Acquired Thrombotic Thrombocytopenic Purpura: A Phase II, Multicenter Non-inferiority Single-arm Study.
Lead sponsor
University Hospital, Rouen
Phase
Phase 2
Overall status
Terminated
Start date
April 26, 2021
Completion date
May 16, 2023
Enrollment
58 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

thrombotic thrombocytopenic purpura, acquired